Ozanimod comment watch save

  • FDA APPROVAL DATE: 03/25/2020
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Cyclosporine, CYP2C8 inhibitors, Breast Cancer Resistance Protein (BCRP) inhibitors, CYP2C8 inducers, MAO inhibitors, adrenergic and serotonergic drugs, opioid drugs, Gemfibrozil, Linezolid, Phenelzine, Rifampin, Selegiline
  • PREGNANCY: No adequate data on the developmental risk associated with the use of ozanimod in pregnant women.

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top